532531 Stock Overview Develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Strides Pharma Science Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Strides Pharma Science Historical stock prices Current Share Price ₹570.30 52 Week High ₹1,675.25 52 Week Low ₹567.70 Beta 0.80 1 Month Change -16.66% 3 Month Change -63.41% 1 Year Change -12.59% 3 Year Change 47.98% 5 Year Change 26.07% Change since IPO 333.69%
Recent News & Updates
Price target decreased by 13% to ₹1,486 Dec 24
Strides Pharma Science Limited completed the Spin-Off of OneSource Specialty Pharma Limited. Dec 12
New major risk - Share price stability Dec 06
Now 59% undervalued after recent price drop Dec 06
Strides Pharma Science Limited Announces Appointment of Dr. C Muthulingam as Executive Vice President - Research & Development Nov 21
Second quarter 2025 earnings released: EPS: ₹10.14 (vs ₹14.54 loss in 2Q 2024) Oct 25 See more updates
Price target decreased by 13% to ₹1,486 Dec 24
Strides Pharma Science Limited completed the Spin-Off of OneSource Specialty Pharma Limited. Dec 12
New major risk - Share price stability Dec 06
Now 59% undervalued after recent price drop Dec 06
Strides Pharma Science Limited Announces Appointment of Dr. C Muthulingam as Executive Vice President - Research & Development Nov 21
Second quarter 2025 earnings released: EPS: ₹10.14 (vs ₹14.54 loss in 2Q 2024) Oct 25
Strides Pharma Science Limited to Report Q2, 2025 Results on Oct 24, 2024 Oct 18
Upcoming dividend of ₹2.50 per share Sep 02 Strides Pharma Science Limited, Annual General Meeting, Sep 25, 2024
Strides Pharma Science Limited Announces Completion of Tenure of S Sridhar as Independent Director Jul 30
First quarter 2025 earnings released: EPS: ₹7.64 (vs ₹0.79 loss in 1Q 2024) Jul 30
Strides Pharma Science Limited to Report Q1, 2025 Results on Jul 29, 2024 Jul 22
Insufficient new directors Jun 24 Strides Pharma Science Limited Announces Chief Financial Officer Changes, Effective June 1, 2024
Price target increased by 20% to ₹994 May 24
Full year 2024 earnings released: ₹13.72 loss per share (vs ₹24.56 loss in FY 2023) May 23
Forecast breakeven date pushed back to 2025 May 23
Strides Pharma Science Limited to Report Q4, 2024 Results on May 22, 2024 May 16
Strides Pharma Science Limited Approves Appointment of Ameet P Hariani as Independent Director May 01
Third quarter 2024 earnings released: ₹0.49 loss per share (vs ₹8.86 loss in 3Q 2023) Jan 31
Price target increased by 10% to ₹730 Jan 31
Strides Pharma Science Limited to Report Q3, 2024 Results on Jan 30, 2024 Jan 23
Strides Pharma Global Pte. Limited Receives USFDA Approval for Generic Suprep®? Bowel Prep Kit Nov 23
Now 21% undervalued Nov 03
Strides Pharma Science Limited Announces Change in Management Oct 31
Second quarter 2024 earnings released: ₹14.54 loss per share (vs ₹0.47 profit in 2Q 2023) Oct 31 Strides Pharma Science Limited to Report Q2, 2024 Results on Oct 30, 2023 Oct 21
New major risk - Revenue and earnings growth Sep 26
Strides Pharma Global Pte. Limited Receives Tentative United States Food & Drug Administration Approval for Dolutegravir Tablets Sep 16
Strides Pharma Science Limited Announces Resignation of Ankit Gupta as Vice President and Head of Corporate Development and Strategy Sep 02
Price target increased by 10% to ₹530 Aug 04
First quarter 2024 earnings released: ₹0.79 loss per share (vs ₹15.13 loss in 1Q 2023) Aug 04
Upcoming dividend of ₹1.50 per share at 0.3% yield Jul 28
Strides Pharma Science Limited to Report Q1, 2024 Results on Aug 02, 2023 Jul 26
Strides Pharma Science Limited Recommends Dividend for Financial Year Ended March 31, 2023 May 26
Full year 2023 earnings: EPS and revenues exceed analyst expectations May 26
Strides Pharma Science Limited to Report Q4, 2023 Results on May 25, 2023 May 19
Price target decreased by 7.2% to ₹462 May 17
Third quarter 2023 earnings released: ₹8.86 loss per share (vs ₹13.55 loss in 3Q 2022) Jan 25
Strides Pharma Science Limited to Report Q3, 2023 Results on Jan 24, 2023 Jan 18
Insufficient new directors Jan 01
Insufficient new directors Nov 16
Strides Pharma Science Limited Announces Resignation of Director Nov 15
Strides Pharma Science Limited to Report Q2, 2023 Results on Nov 14, 2022 Nov 09
Strides Pharma Science Limited, Annual General Meeting, Sep 09, 2022 Aug 19
Strides Pharma Science Limited, Annual General Meeting, Sep 09, 2022 Aug 18
First quarter 2023 earnings released: ₹15.13 loss per share (vs ₹22.88 loss in 1Q 2022) Jul 30
Strides Pharma Science Limited to Report Q1, 2023 Results on Jul 29, 2022 Jul 23
Stelis Biopharma Limited and Strides Pharma Science Limited Receive the European Union Goods Manufacturing Practices (EU-GMP) Compliance Certificate Jun 17
Strides Receives USFDA Approval for Ibuprofen Oral Suspension May 31
Full year 2022 earnings: EPS misses analyst expectations May 26
Strides Pharma Science Limited to Report Q4, 2022 Results on May 24, 2022 May 17
Price target decreased to ₹463 Apr 27
Insufficient new directors Apr 27
Insufficient new directors Apr 01 Strides Pharma Science Limited Announces Executive Changes
Founder & Non-Executive Chairman recently bought ₹50m worth of stock Mar 05
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Feb 13 Strides Pharma Science Limited announced that it expects to receive INR 485 million in funding from Karuna Business Solutions LLP Feb 11
Price target decreased to ₹735 Nov 12
Second quarter 2022 earnings released: ₹18.12 loss per share (vs ₹7.38 profit in 2Q 2021) Nov 11
Insider recently sold ₹1.5m worth of stock Sep 23
Price target decreased to ₹857 Sep 15
Insider recently sold ₹14m worth of stock Aug 14
First quarter 2022 earnings released: ₹22.88 loss per share (vs ₹11.56 profit in 1Q 2021) Aug 09
Less than half of directors are independent Aug 07
Upcoming dividend of ₹2.50 per share Jul 29
Insider recently sold ₹2.8m worth of stock Jul 03
Chief Human Resource Officer recently sold ₹4.1m worth of stock Jun 18
Full year 2021 earnings released: EPS ₹28.40 (vs ₹5.49 in FY 2020) May 30 TLC and Strides Pharma Science Limited Partner to Launch Liposomal Amphotericin B in India
Third quarter 2021 earnings released: EPS ₹4.22 (vs ₹10.48 in 3Q 2020) Feb 05
Price target raised to ₹886 Feb 05
Revenue and earnings miss expectations Feb 05
Strides Pharma Science Limited to Report Q3, 2021 Results on Feb 04, 2021 Jan 29
Aditya Puri Joins as Advisor to the Strides Group Jan 09
Strides Pharma Reportedly May Get Transferred to A Clutch of Investors as Promoters Plan to Exit Dec 31
New 90-day high: ₹901 Dec 28
Insider recently sold ₹1.3m worth of stock Dec 12
Insider recently sold ₹3.1m worth of stock Dec 04
New 90-day high: ₹764 Nov 27
Second-quarter earnings released: Revenue misses expectations Nov 01
First half earnings released Nov 01
Price target raised to ₹786 Nov 01
New 90-day high: ₹729 Oct 07
Pronomz Ventures LLP completed the acquisition of 3.7% stake in Strides Pharma Science Limited (NSEI:STAR) from Sequent Scientific Limited (BSE:512529) Sep 26
Price target raised to ₹703 Sep 24
Insider recently sold ₹399m worth of stock Sep 18
New 90-day high - ₹686 Sep 11
Non-Executive Director recently bought ₹4.6m worth of stock Aug 28 Shareholder Returns 532531 IN Pharmaceuticals IN Market 7D -8.7% 1.5% 3.4% 1Y -12.6% 27.7% 11.3%
See full shareholder returns
Return vs Market: 532531 underperformed the Indian Market which returned 11.3% over the past year.
Price Volatility Is 532531's price volatile compared to industry and market? 532531 volatility 532531 Average Weekly Movement 15.9% Pharmaceuticals Industry Average Movement 6.0% Market Average Movement 6.3% 10% most volatile stocks in IN Market 9.1% 10% least volatile stocks in IN Market 4.2%
Stable Share Price: 532531's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: 532531's weekly volatility has increased from 9% to 16% over the past year.
About the Company Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams.
Show more Strides Pharma Science Limited Fundamentals Summary How do Strides Pharma Science's earnings and revenue compare to its market cap? 532531 fundamental statistics Market cap ₹52.59b Earnings (TTM ) ₹1.77b Revenue (TTM ) ₹44.10b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 532531 income statement (TTM ) Revenue ₹44.10b Cost of Revenue ₹19.25b Gross Profit ₹24.85b Other Expenses ₹23.08b Earnings ₹1.77b
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 19.21 Gross Margin 56.35% Net Profit Margin 4.01% Debt/Equity Ratio 100.0%
How did 532531 perform over the long term?
See historical performance and comparison Dividends
0.4% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/21 01:05 End of Day Share Price 2025/01/21 00:00 Earnings 2024/09/30 Annual Earnings 2024/03/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Strides Pharma Science Limited is covered by 20 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Aditya Khemka Ambit Capital Harith Ahamed Avendus Spark Prakash Agarwal Axis Capital Limited
Show 17 more analysts 
